Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
Authors:
- 15 November 2018
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (1) , 105-111
Abstract
Objective: In the absence of head-to-head trials, this study indirectly compared progression free survival (PFS) and overall survival (OS) between ceritinib and crizotinib among patients with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Methods: A matching-adjusted indirect comparison method was implemented to adjust for cross-trial differences in patient characteristics between ASCEND-4 and PROFILE 1014 trials. Patient-level data from ASCEND-4 and published summary data from PROFILE 1014 were used. Patients in ASCEND-4 were reweighted to match average baseline characteristics (i.e., age, sex, race, tumor histology, ECOG score, smoking status, extent of disease, and presence of brain metastases) reported for PROFILE 1014 patients using propensity score weighting. PFS and OS were then compared between balanced populations. Results: ASCEND-4 included more current smokers (8.0% vs. 4.4%) and fewer patients under the age of 65 years (78.5% vs. 84.0%) compared to PROFILE 1014. After matching, these and all other patient characteristics were balanced between the two trial populations. Compared to crizotinib, ceritinib was associated with a significantly longer PFS (hazard ratio [95% confidence interval] (HR: [CI]) = 0.64 [0.47, 0.87]; median PFS: 25.2 vs. 10.8 months, log-rank p-value =0.003). OS did not differ significantly, with a HR of 0.82 [0.54, 1.27] for ceritinib compared to crizotinib. Conclusions: In the adjusted indirect comparison with external controls, the second generation ALK inhibitor, ceritinib, was associated with a significantly prolonged PFS compared to crizotinib as first-line treatment for ALK-positive NSCLC.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation.
This publication has 29 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trialsCurrent Medical Research and Opinion, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Comparative Effectiveness Without Head-to-Head TrialsPharmacoEconomics, 2010
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Annals of Oncology, 2010
- Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trialsBritish Journal of Clinical Pharmacology, 2008
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyBlood, 2006
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983